PMDA Eyes 15-20% New Drug Review Fee Raise in April, Plan Now Up for Public Comments

The Pharmaceuticals and Medical Devices Agency (PMDA) is looking to raise its review fees for new drugs by 15-20% from April 1, with the plan now put up for public comments through March 9. Issuing an invitation for public comments,...read more